Results 11 to 20 of about 2,566,374 (138)

Urate-lowering therapy and kidney function [PDF]

Современная ревматология, 2023
Chronic hyperuricemia (CH) and gout are independent risk factors for decreased kidney function. In the last decade, evidence was accumulating that urate-lowering therapy may be an effective method of slowing down the progression of CH and gout-mediated ...
M. S. Eliseev
core   +3 more sources

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 – 4 chronic kidney disease: Controversial role of kidney function

PLoS ONE, 2019
Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD).
Hee Jung Jeon (3663334), Jieun Oh, Jieun Oh (783748), Dong Ho Shin, Dong Ho Shin (299513), Hee Jung Jeon   +5 more
core   +2 more sources

Urate-lowering drugs in the treatment of gout: The unknown about the known [PDF]

Научно-практическая ревматология, 2021
The main direction of drug therapy for gout and other diseases associated with hyperuricemia is the long-term use of drugs aimed at correcting the level of uric acid.
T. S. Panevin, E. L. Nasonov, M. S. Eliseev   +2 more
core   +3 more sources

Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis? [PDF]

Exploration of Musculoskeletal Diseases
Co-prescription of anti-inflammatory prophylaxis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids when initiating urate-lowering therapy (ULT) for gout is recommended in clinical guidelines to prevent ULT-induced flares
Mallen, Christian D., Prior, James A., Roddy, Edward   +2 more
core   +2 more sources

Spinal gout recovery with urate-lowering therapy: A case report. [PDF]

Clin Case Rep
Key Clinical Message The occurrence of spinal gout resulting in erosion of the superior articular process in patients with low back pain is uncommon, potentially leading to misdiagnosis and inappropriate treatment.
Huo K, Zhang J, Lin Y, Chen Q, Zhong H, Yang B.   +5 more
europepmc   +3 more sources

Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy [PDF]

Acta Biomedica Scientifica, 2021
Background. Gout is frequently accompanied by hypertension, obesity, and/or impaired glucose tolerance, which are often complicated with heavy smoking and dietary violations, especially in male patients.Objective.
N. Y. Oshmianska, J. Chen, W. Tan, P. Zhou, M. Zheng   +4 more
core   +3 more sources

Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout [PDF]

Научно-практическая ревматология, 2019
During the first months after initiation of urate-lowering therapy in patients with gout, the risk of exacerbating arthritis substantially increases, frequently causing them to refuse this treatment.
M. N. Chikina
core   +3 more sources

Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound

Kidney & Blood Pressure Research, 2018
Current urate-lowering therapy (ULT) includes three direct acting drugs (allopurinol, febuxostat, Rasburicase) and at least four ‘indirect’ drugs with other important targets (canagliflozin, losartan, fenofibrate and sevelamer).
Anna Giammarino, Capasso, Giovambattista, Michelangelo Nigro, Giovambattista Capasso, Viggiano, Davide, Gigliotti, Giuseppe, Davide Viggiano, Nigro, Michelangelo, Gianfranco Vallone, Vallone, Gianfranco, Giuseppe Gigliotti, Giammarino, Anna   +11 more
core   +2 more sources

Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol.

International Journal for Equity in Health, 2022
BackgroundGout is a painful chronic disease which disrupts work and family life and can lead to chronic joint damage. Pacific people in Aotearoa/New Zealand experience significant inequities, with over three times the gout prevalence of the non-Pacific ...
Ofanoa, Samuela Malakai, Dalbeth, Nicola, Grey, Corina, Lutui, Hinamaha, Ofanoa, Malakai, Heather, Maryann, Goodyear-Smith, Felicity, van der Werf, Bert, Tu'akoi, Siobhan   +8 more
core   +2 more sources

OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts

Frontiers in Pharmacology, 2022
Dysfunctional missense variant of organic anion transporter 10 (OAT10/SLC22A13), rs117371763 (c.1129C>T; p.R377C), is associated with a lower susceptibility to gout.
Yu Toyoda, Yu Toyoda, Yusuke Kawamura, Akiyoshi Nakayama, Keito Morimoto, Seiko Shimizu, Yuki Tanahashi, Takashi Tamura, Takaaki Kondo, Yasufumi Kato, Kimiyoshi Ichida, Hiroshi Suzuki, Nariyoshi Shinomiya, Yasushi Kobayashi, Tappei Takada, Hirotaka Matsuo   +15 more
doaj   +1 more source